作者:Nis Halland、Horst Blum、Christian Buning、Markus Kohlmann、Andreas Lindenschmidt
DOI:10.1021/ml4004556
日期:2014.2.13
Starting from clinical candidates Firategrast, Valategrast, and AJM-300, a series of novel macrocyclic platelet collagen receptor alpha 2 beta 1 antagonists were developed. The amino acid derived low molecular weight 14-18-membered macrocycles turned out to be highly active toward integrin alpha 2 beta 1 with IC(50)s in the low nanomolar range. The conformation of the macrocycles was found to be highly important for the activity, and an X-ray crystal structure was obtained to clarify this. Subsequent docking into the metal-ion-dependent adhesion site (MIDAS) of a beta 1 unit revealed a binding model indicating key binding features. Macrocycle 38 was selected for further in vitro and in vivo profiling.